The Toxic Substances Control Act (TSCA); One of the most influential regulatory levers to remove toxic chemicals from building and consumer products

Case Study: Formaldehyde & Asthma

March 9, 2023





I have no conflicts to disclose



Our system to regulate toxic chemicals is not working and puts people and communities in harms way





Toxic Substances Control Act

What is TSCA?

- Enacted in 1976 to give EPA authority to regulate chemicals in commerce
- Covers all chemicals except for categories like drugs, cosmetics, food additives, and pesticides
- Chemicals already in commerce were/still are assumed to be safe until shown harmful
- In 40 years between original TSCA & 2016 amendments, EPA regulated < 10 of over 86 000 chemicals registered for use in commerce



Amended TSCA requires EPA to:

- Consider risks to "potentially exposed or susceptible subpopulations" (PESS) and determine if a chemical poses an "unreasonable risk" without consideration of cost
- Regulate any existing chemical determined to pose an unreasonable risk "to the extent necessary so that the chemical substance or mixture no longer presents such risk"
- Use "information, technical procedures, measures, use scientific methods, protocols, methodologies, or models, employed in a manner consistent with the best available science"




But.... TSCA is Broken

Since EPA's implementation of amended TSCA there have been:

We recommend that EPA

10 Final Risk Evaluations



p-Dichlorobenzene	Di-isobutyl phthalate (DIBP)		
1,2-Dichloroethane	Dicyclohexyl phthalate		
trans-1,2- Dichloroethylene	Dibutyl phthalate (DBP)		
o-Dichlorobenzene	Butyl benzyl phthalate (BBP)	•	
1,1,2-Trichloroethane	Di-ethylhexyl phthalate (DEHP)		
1,2-Dichloropropane	Ethylene dibromide		
1,1-Dichloroethane	1,3-Butadiene		
4,4'-(1- Methylethylidene)bis[2, 6- dibromophenol] (TBBPA)	ННСВ		
Tris(2-chloroethyl) phosphate (TCEP)	Formaldehyde		
Phosphoric acid, triphenyl ester (TPP)	Phthalic anhydride		

Next 20 High Priority Chemicals EPA is evaluating

Chlorinated solvents

Flame retardants

Phthalates



Under Amended TSCA EPA must use the best available science to evaluate the impact of toxic chemicals and make decisions that protect human health and the environment

However...

EPA currently has **no method to quantify health risks for non-cancer effects of toxic chemicals**... so they can't quantify the health risks of outcomes like asthma, diabetes, dementia, CVD etc

Health risk from environmental chemical exposure is assessed differently for **cancer** versus **non-cancer** health effects

Non-cancer Health Effects:


There are "safe"* exposure levels that don't increase risk of disease.

Cancer:

Any exposure increases risk of cancer.

*The assumption of a "safe level" is fundamentally flawed, as it does not sufficiently account for human variability and the many factors that make some people more susceptible than others.


Formaldehyde & Asthma Case Study: Why Formaldehyde?











Formaldehyde History

I990I9982010US EPA releasesUS EPA IRISUS EPA IRISIRIS assessment ofinitiatedreleases draftformaldehydereassessment ofassessment forformaldehydereviewreview

2011 NAS published independent review of formaldehyde report Dec 2016 EPA releases final formaldehyde rule for standards in composite wood products (as mandated by TSCA), no inclusion of asthma outcomes




EPA Benefits Valuation

Table ES-12-9:: Total Annualized Costs, Benefits, and Net Benefits for All Options (millions 2010\$, 3 percent discount rate)

Analytical Option	C	osts	Benefits		Net Benefits			
	Low End	High End	Lower	Higher	Lower	Higher		
	Estimate	Estimate	Estimate	Estimate	Estimate	Estimate		
Option SE	\$100	\$100	\$ 162 18 +B	\$ 245<u>42+</u>B	\$62(\$82) +B	\$145 (\$58) +B		
Option SI	\$ 194 204	\$293	\$ 184-<u>20</u> + B	\$ 278<u>48+</u> B	(\$ 109) 273) +B	\$84 <u>(</u>\$157) +B		
Option SP	\$104	\$104	Not estimated	Not estimated	Not estimated	Not estimated		
Option SN	\$ 143 128	\$ 185 137	\$ 192 21+ B	\$289 <u>50+ B</u>	\$7 <u>(\$116) +B</u>	\$146 <u>(\$79) +B</u>		
Option SC	\$112	\$121	\$ 184<u>20+</u>B	\$ 278<u>48+</u>B	\$63(\$101) +B	\$166(\$64)+B		
Option SCR	\$72	<u>\$81</u>	<u>\$20+ B</u>	<u>\$48+ B</u>	(\$61) +B	<u>(\$24) +B</u>		
Option SEUR	<u>\$60</u>	<u>\$60</u>	<u>\$18+ B</u>	<u>\$42+ B</u>	<u>(\$42) +B</u>	<u>(\$18) +B</u>		
Option SFCC	\$100	\$100	<u>\$18+ B</u>	<u>\$42+ B</u>	<u>(\$82) +B</u>	<u>(\$58) +B</u>		
Option SCRSCUR (proposed)	\$72	\$81	\$ 184<u>20+</u> B	\$ 278<u>48+</u> B	\$103(\$60) +B	<u>\$206(\$24) +B</u>		
Option CE	\$99	\$99	\$ 125<u>14+B</u>	\$188 <u>32+ B</u>	\$25(\$86) +B	\$89 <u>(\$67) +B</u>		
Option CI	\$ 192 203	\$292	\$ 142<u>16+</u> B	\$ 214<u>37+</u>B	(\$ 150) 277) <u>+B</u>	\$22(\$167) +B		
Option NE	\$379	\$379	\$ 639<u>76+</u> B	\$ 970<u>178+</u> B	\$259(\$303) +B	\$591(\$201) +B		
Option NI	\$473 <u>484</u>	\$573	\$ 667<u>80+</u> B	\$ 1,013<u>186+</u>B	\$94(\$493) +B	\$540(\$297) +B		
Option SCRSCUR is the proposed option. Parentheses indicate negative net benefits. Lower estimate of net benefits is calculated by subtracting high end cost estimate from lower benefits estimate. Higher estimate of net benefits is calculated by subtracting low end cost estimate from higher benefits estimate. "B" represents the unquantified health benefits. Slide borrowed from Charles Griffiths								

EPA Benefits Valuation



13

Formaldehyde & Asthma Case Study

Review evidence of health benefits of preventing exposure to formaldehyde

- Systematic review of formaldehyde & asthma
- Produce concise, transparent and actionable conclusion
- Combine dose-response info with cost/incidence rates of asthma to monetize benefits of avoiding asthma
- Capture process of influencing change






- \rightarrow Our case study illustrates how using robust methods of
 - \rightarrow Systematic review
 - \rightarrow Dose response of noncancer endpoints
 - \rightarrow Benefits assessment down to zero

Can **improve use** of science in decision-making to better protect health




Meta-Analysis for Children Asthma Diagnosis



Indoor exposure to formaldehyde <u>significantly</u> <u>associated</u> with increased odds— <u>8% increase per</u> <u>10-fold exposure</u>) for children's asthma diagnosis



Meta-Analysis for Children Asthma Symptoms



Indoor exposure to formaldehyde showed increased odds—8% increase per 10fold exposure for children's asthma symptoms in (wheeze, shortness of breath), but not statistically significant

S

Benefit-cost analysis

- Outcome: avoiding a case of asthma in children
- Full implementation of EPA's proposed rule on pressed wood products results in 2,805 fewer asthma cases annually
- Willingness to pay = \$75,024 annually

\$90 million across all children in the US over 30 years



Benefit-cost analysis

Proposed rule \$184 - 278 million \$72 - 81 million

OMB-modified rule

18

\$20 - 48 million\$72 - 81 millionLam et al. benefit estimates\$210 million>>\$72 - 81 million

Benefits outweigh

costs

Lessons learned from formaldehyde


- Authors concluded there was "sufficient" evidence supporting associations between childhood and adult formaldehyde exposures with asthma diagnosis and symptoms
- Even with relatively "small" risks (8% increase), with ubiquitous exposures and chronic health outcomes the benefits can be significant
- Critical for policy decisions to account for all relevant health outcomes to avoid underestimation of benefits

A Science-Based Agenda for Health-Protective Chemical Assessments and Decisions

 Strategic and specific scientific-based recommendations to improve key aspects of chemical hazard and risk assessment to support improved policy decisions that better protect public health

> **Science Action Network** FOR HEALTH AND THE ENVIRONMENT





Concrete next step

Account for conflicts of interest in risk assessments

A Science-Based Agenda for Health-Protective Chemical Assessments and Decisions


Improve its inadequate approach to **exposure assessments** that have prevented the Agency from fully protecting communities



Update methods to consider **population variability** and increase protection for people burdened by environmental exposures and/or social stressors such as poverty and racism



Adopt a **class-based approach** to evaluate chemical risks rather than evaluating hazardous chemicals one at a time



Quantify **non-cancer health outcomes** to better reflect real-world health consequences of exposures and improve benefit-cost analyses of regulations



Recommendations

Regulators should:

- Incorporate probabilistic doseresponse methods into risk assessments
- 2. Quantify non-cancer health risks across the range of exposure levels
- 3. Consider severity of health effect and how many people are affected when selecting acceptable exposure levels



President Biden's Regulatory Review Memo

"take into account the distributional consequences of regulations...to ensure that regulatory initiatives appropriately benefit and do not inappropriately burden disadvantaged, vulnerable, or marginalized communities".

U.S. Executive Office of the President. Presidential Memorandum, Modernizing Regulatory Review, § 2(b)(i), **2021**

How Can You Engage?

- Regular meetings with EPA
- Risk Evaluation Engaging with comments process and ensuring EPA applies these methods
- Risk Management Engaging in the consultations and commenting on chemical management as it relates to your jurisdiction



Program on Reproductive Health and the Environment

Science | Policy | Education | Communications

YOU'RE INVITED

Greetings,

We are inviting you to join us on Capitol Hill in Washington, DC, **Wednesday, March 29, at 1 PM ET** for a legislative briefing where we will discuss how the U.S. Environmental Protection Agency (EPA) can use the best available science to better protect people and highly impacted communities from harmful chemicals.

Due to security at the Capitol Building, you must be registered to attend. Register here: <u>bit.ly/chb2023</u>









